Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nicolas Lalor"'
Autor:
Marcos Viruel, Florencia Muñoz, Cristian Garmendia, Leandro Parrilla, Carlos Ruano, Mirza Rivero, Ezequiel Zaidel, Nicolas Lalor, Gonzálo Pérez, Juan P. Costabel
Publikováno v:
Revista Argentina de Cardiologia. 90:105-111
Background: The POPular AGE study demonstrated that in patients over 70 years of age clopidogrel would be the P2Y12 receptor inhibitor (P2Y12i) of choice due to its association with lower bleeding incidence and no difference in ischemic events. Objec
Autor:
Nicolas, Lalor, Leandro, Rodríguez, Pablo, Elissamburu, Eduardo, Filipini, Diego, Conde, Gerardo, Nau, Fernando, Cura, Marcelo, Trivi
Publikováno v:
Medicina. 75(4)
Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS). This study was aimed at comparing the incidence
Publikováno v:
The American journal of emergency medicine. 32(2)
Autor:
Diego, Conde, Pablo, Elissamburu, Nicolas, Lalor, Leandro, Rodriguez, Martin, Aragon, Juan Pablo, Costabel, Florencia, Lambardi, Marcelo, Trivi
Publikováno v:
Journal of atrial fibrillation. 6(2)
Introduction: Vernakalant is a new, safe and effective drug used intravenously. It has proven to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone and flecainide in clinical
Publikováno v:
The American journal of emergency medicine. 31(8)
Publikováno v:
The American journal of emergency medicine. 31(8)
Publikováno v:
The American Journal of Emergency Medicine. 31:1286-1287
Publikováno v:
The American Journal of Emergency Medicine. 31:1287-1288
Publikováno v:
The American Journal of Emergency Medicine. 32:467
Publikováno v:
Global Heart. 9:e62